When the first boxes of weight-loss pills flown in from Denmark hit Australian pharmacy shelves late last week, investors and patients watched closely.
There has been a lot of noise about the benefits and side effects of GLP-1s made famous by celebrities and social media influencers, but less attention to the vast sums of money the most successful drug rollout in decades is making – not only for big pharmaceutical companies, but also for the companies selling them.
Gift articles to anyone you choose each month when you subscribe.